Marinomed’s Antiviral polymer awarded Chinese patent

Published on November 18, 2012 at 11:52 PM · No Comments

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has been granted Chinese Patent No. CN101678040, entitled 'Antiviral polymer', by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.

Dr. Andreas Grassauer, CEO and co-founder of Marinomed, commented:

"The national granting of this patent is an important further step in protecting Marinomed's intellectual property and know-how around our anti-viral product portfolio based on our mavirex technology platform. Furthermore this patent contributes value in the out-licensing of our products or technology to partner companies in China."

Marinomed has an anti-viral product portfolio for the prevention and treatment of common cold and influenza. The products include the patent protected polymer Carragelose®; a polymer of the mavirex technology platform. Marinomed's anti-viral OTC portfolio is already marketed in- and out-side of the EU. The lead product is an anti-viral nasal spray against common cold for adults and children starting from age 1, pregnant and breastfeeding women.


Marinomed Biotechnologie

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Drexel study provides new insight into future treatment of breathing disorders